Nasdaq · CIK 0001831915
CTKB Cytek Biosciences, Inc.
A
95 / 100
Material weaknesses
1
Restatements
0
Auditor changes
0
Late filings
0
Quarters with open weakness
1
Remediations
1
Deductions
20
Remediation credit
15
Trailing 24 months from 2024-11-07. Rubric v1. How this is scored.
Disclosures, in the company's words
“In prior periods, certain filings were made pursuant to Rule 12b-25, and adjustments were made to certain line items in the related financial statements.”
“In connection with our financial statement close process for the year ended December 31, 2024, we identified deficiencies in the control environment and control activities components of the Committee of Sponsoring Organizations ( COSO ) framework that constitute material weaknesses, either individually or in the aggregate.”
Remediation disclosed
- 10-Q · filed 2026-11-04 · source filing ↗
“While the identified material weaknesses were remediated in fiscal year 2025, we cannot provide assurance that we will not identify additional material weaknesses in future periods”
Filings read
- 10-Q · 2026-11-04read
- 10-Q · 2026-08-05queued
- 10-Q · 2026-05-07queued
- 10-K · 2026-02-26queued
- 10-Q · 2025-11-05queued
- 10-Q · 2025-08-06queued
- 10-Q · 2025-05-08queued
- 10-K · 2025-02-28queued
- 10-Q · 2024-11-07queued
Think something here is wrong? Request a correction. Open corrections hide the affected disclosure until resolved.